OncoMatch/Clinical Trials/NCT06496373
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
Is NCT06496373 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Fixed neoantigen tumor vaccine and personalized neoantigen tumor vaccine for pancreatic cancer resectable.
Treatment: Fixed neoantigen tumor vaccine · personalized neoantigen tumor vaccine · PD-1 inhibitor — This study primarily aims to assess the safety and tolerability of XP-004 personalized mRNA vaccines encoding tumor neoantigens combined with PD-1 inhibitor as adjuvant therapy for chemotherapy-intolerant patients following radical pancreatic cancer resection. Secondary objectives focus on evaluating preliminary efficacy through three parameters: 1) XP-004-induced antigen-specific CD4+/CD8+ T cell activation levels, 2) recurrence-free survival (RFS), and 3) overall survival (OS) in post-operative pancreatic cancer patients receiving this combination therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Prior therapy
Must have received: surgery — radical
have undergone radical surgery for pancreatic malignant tumors for 1-3 months
Cannot have received: chemotherapy
Has had chemotherapy...within 4 weeks prior to the first administration of the study drug
Cannot have received: traditional Chinese medicine with antitumor indications
Has had...traditional Chinese medicine with antitumor indications...within 4 weeks prior to the first administration of the study drug
Cannot have received: other antitumor therapies deemed to conflict with the current treatment by the investigator
Has had...other antitumor therapies deemed to conflict with the current treatment by the investigator within 4 weeks prior to the first administration of the study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify